Syntiron’s antigen discovery and purification technology targets the bacterial iron transport proteins that are critical for causing an infection.


News and Events

Syntiron recently completed a successful NIH Phase I SBIR Project to develop an E. coli vaccine to prevent urinary tract infections. Stay tuned for more updates on the project.